Insights On Drug Development

  1. AustinPX Site Tour 5/2/2025

    Take a virtual tour of AustinPx to explore advanced facilities, including KinetiSol™ technology, and discover how we enable scalable, sustainable performance.

  2. ADC Heterogeneity, Site-Specific Conjugation 4/29/2025

    This busy segment of the Bioprocess Online Live panel discussion Accelerating ADC Process Development finds Dr. Léo Marx (Debiopharm), Dr. Monika Lamba Saini (ADC Therapeutics), and Dr. Philipp Spycher (Araris Biotech) addressing DAR variability and lipophilic toxicity, homogeneity, computational tools to address molecular design and ADC behavior, and revisiting strategic considerations in CDMO selection before addressing a second live poll of our audience. 

  3. Linker And ADC Platform Manufacturing Technologies 4/29/2025

    In this segment from the Bioprocess Online Live panel discussion Accelerating ADC Process Development, Dr. Léo Marx (Debiopharm) addresses advances in linker technology before he, Dr. Monika Lamba Saini (ADC Therapeutics) and Dr. Philipp Spycher (Araris Biotech) answer audience questions about the feasibility of developing a platform for ADC development, IP considerations for proprietary technologies, and outsourcing vs. in-house manufacturing approaches.

  4. Challenges In ADC Process Development 4/29/2025

    Where does ADC process development fail? In this segment from the Bioprocess Online Live panel discussion Accelerating ADC Process Development, expert panelists Dr. Monika Lamba Saini (ADC Therapeutics), Dr. Léo Marx (Debiopharm), and Dr. Philipp Spycher (Araris Biotech) address audience questions on target identification cleanliness and payload challenges before we turn the tables on the audience with a question on their biggest challenges.

  5. AI In ADC Target Identification 4/29/2025

    How are AI and machine learning contributing to ADC target identification and early development? Dr. Monika Lamba Saini (ADC Therapeutics), Dr. Léo Marx (Debiopharm), and Dr. Philipp Spycher (Araris Biotech) tackle computational approaches to protein targets, clinical implications of target expression and internalization, and AlphaFold AI-driven pathology in this segment from the Bioprocess Online Live panel discussion Accelerating ADC Process Development.

  6. ADCs & Speed To IND 4/29/2025

    In this opening segment from the Bioprocess Online Live panel discussion Accelerating ADC Process Development, expert panelists Dr. Monika Lamba Saini (ADC Therapeutics), Dr. Léo Marx (Debiopharm), and Dr. Philipp Spycher (Araris Biotech) frame up ADC development challenges—including molecular complexity, regulatory and analytical hurdles, and strategic logistical manufacturing. We discuss those challenges in the context of the burgeoning industry’s breakneck development timelines leading up to IND submission.

  7. Formulation Strategies For Enabling "Undevelopable" Compounds 4/29/2025

    KinetiSol enhances bioavailability of poorly soluble drugs like Vemurafenib by producing dense amorphous dispersions, outperforming traditional MBP methods in pharmacokinetics and dissolution.

  8. Protein Stress Testing 4/28/2025

    Start your forced degradation studies early to uncover molecular risks, strengthen product stability, and ensure regulatory-ready development from the start.

  9. Stability Screening For Colloidal Stability: Diffusion Interaction Parameter Thermal Shift Assay 4/28/2025

    Colloidal stability is one of the most important properties to control due to the propensity for biopharmaceuticals to aggregate and the subsequent potential to severely affect the drug's efficacy and patient safety.

  10. Why Cell Line Screening Is Crucial For Successful CDC Assay Development 4/28/2025

    In developing a CDC assay for therapeutic mAb characterization or QC release testing, in addition to selecting a target cell line that expresses the mAb ligand, consideration should be made to the expression of CRPs on the cell surface.